On July 16, 2025, Edwards Lifesciences (EW, Financial) received a continued vote of confidence from Mizuho analyst Anthony Petrone. Petrone maintained an "Outperform" rating on the stock, underscoring a positive outlook for the company's future performance.
The analyst raised the price target for Edwards Lifesciences (EW, Financial) from a previous target of $85.00 to a new target of $87.00. This adjustment represents a 2.35% increase in the target price, reflecting anticipated growth and valuation improvements.
This move by Mizuho aligns with the company's current market trajectory. Investors in Edwards Lifesciences (EW, Financial) may view this enhanced price target as a promising indication of potential returns and market confidence in the company's strategic direction.
The stock trades on the NYSE, and this updated analyst view could influence investor sentiment and market activities regarding Edwards Lifesciences (EW, Financial) in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 27 analysts, the average target price for Edwards Lifesciences Corp (EW, Financial) is $82.05 with a high estimate of $95.00 and a low estimate of $61.00. The average target implies an upside of 6.82% from the current price of $76.81. More detailed estimate data can be found on the Edwards Lifesciences Corp (EW) Forecast page.
Based on the consensus recommendation from 34 brokerage firms, Edwards Lifesciences Corp's (EW, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Edwards Lifesciences Corp (EW, Financial) in one year is $105.91, suggesting a upside of 37.89% from the current price of $76.81. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Edwards Lifesciences Corp (EW) Summary page.
